Clinical Trials on Hormone Refractory Prostate Cancer in United States
Total 6880 results
-
University of California, IrvineBristol-Myers SquibbCompletedRecurrent Prostate Cancer | Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Hormone-refractory Prostate CancerUnited States
-
Veeda OncologyBayerTerminatedHormone Refractory Prostate CancerUnited States
-
University of FloridaCureVacTerminated
-
CytRxCompletedHormone Refractory Prostate CancerUnited States
-
Queen's Medical CenterNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedHormone Refractory Prostate CancerUnited States
-
David M LubaroffUnited States Department of DefenseCompletedHormone Refractory Prostate CancerUnited States
-
Duke UniversityUnited States Department of DefenseCompletedMetastatic Hormone Refractory Prostate CancerUnited States
-
Daniel George, MDNovartis PharmaceuticalsCompletedHormone Refractory Prostate CancerUnited States
-
Ascenta TherapeuticsCompletedHormone Refractory Prostate CancerUnited States
-
PfizerAstellas Pharma Inc; Medivation LLC, a wholly owned subsidiary of Pfizer Inc.CompletedProstate Cancer | Hormone Refractory Prostate CancerUnited States
-
CelgeneCompletedHormone Refractory Prostate CancerUnited States
-
Novartis PharmaceuticalsTerminatedHormone Refractory Prostate Cancer DiseaseUnited States
-
Novartis PharmaceuticalsTerminatedHormone Refractory Prostate CancerUnited States
-
DendreonCompletedHormone Refractory Prostate Cancer | Castration-resistant Prostate Cancer | Prostate Cancer MetastaticUnited States
-
Merrion Pharmaceuticals, LLCCompletedHormone-Refractory Prostate CancerUnited States, Estonia, Latvia
-
National Cancer Institute (NCI)CompletedRecurrent Prostate Cancer | Hormone Refractory Prostate CancerUnited States, Canada
-
Sandy SrinivasWyeth is now a wholly owned subsidiary of Pfizer; American Society of Clinical... and other collaboratorsTerminatedProstatic Neoplasms | Prostate Cancer | Metastatic Disease | Hormone-refractory Prostate Cancer | Castrate-resistant Prostate Cancer (CRPC) | Androgen-insensitive Prostate CancerUnited States
-
Ascenta TherapeuticsCompletedHormone Refractory Prostate CancerUnited States, Russian Federation
-
Stanford UniversityTerminatedProstatic Neoplasms | Prostate Cancer | Metastatic Disease | Hormone-refractory Prostate Cancer | Castrate-resistant Prostate Cancer (CRPC) | Androgen-insensitive Prostate CancerUnited States
-
Oxford BioMedicaMedSource LLCTerminatedHormone Refractory Prostate CancerUnited States
-
Genzyme, a Sanofi CompanyCompletedHormone-refractory Prostate CancerUnited States
-
Achieve Life SciencesTeva Pharmaceuticals USATerminatedHormone Refractory Prostate Cancer | Castrate-Resistant Prostate CancerFrance, United States, Spain, United Kingdom, Canada
-
AgennixCompletedProstate Cancer | Hormone Refractory Prostate CancerUnited States, United Kingdom, France, Italy, Israel, Germany, Hungary, Argentina, Russian Federation, Belgium, Croatia, Netherlands, Peru, Poland, Spain
-
Novartis PharmaceuticalsCompletedMetastatic Hormone Refractory Prostate CancerUnited States, France, Spain, Belgium, Singapore, Italy, Australia, Germany
-
University of Alabama at BirminghamMerck Sharp & Dohme LLCCompletedProstate Cancer | Hormone Refractory Prostate CancerUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer | Hormone-refractory Prostate CancerUnited States
-
University of Michigan Rogel Cancer CenterNovartis; Aventis PharmaceuticalsCompletedHormone-Refractory Prostate CancerUnited States
-
Astellas Pharma IncAstellas Pharma US, Inc.TerminatedProstatic Neoplasms | Hormone-Refractory Prostate CancerUnited States, Ireland, Australia, France, United Kingdom, Belgium, Germany, Netherlands, Poland, Spain
-
GenesisCare USADendreonCompletedCastrate Refractory Metastatic Prostate Cancer (mCRPC)United States
-
Washington University School of MedicineBristol-Myers Squibb; ExelixisActive, not recruitingMetastatic Hormone Refractory Prostate CancerUnited States
-
Northwestern UniversityRecruitingMetastatic Prostate Carcinoma | Recurrent Prostate Carcinoma | Stage IV Prostate Cancer | Hormone-Refractory Prostate Cancer | Castration-Resistant Prostatic CancerUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Bayer; Janssen, LP; Prostate Cancer Clinical Trials ConsortiumCompletedStage IV Prostate Adenocarcinoma | Hormone-refractory Prostate Cancer | Prostate Carcinoma Metastatic to the BoneUnited States
-
ImmuniconUnknownProstate Cancer | Hormone Refractory Prostate CancerUnited States
-
Institute of Cancer Research, United KingdomRoyal Marsden NHS Foundation Trust; Nottingham University Hospitals NHS Trust; Barts & The London NHS Trust and other collaboratorsRecruitingHormone Refractory Prostate CancerUnited Kingdom
-
Amunix, a Sanofi CompanyRecruitingHormone-refractory Prostate CancerAustralia, Spain, United Kingdom
-
Sidney Kimmel Comprehensive Cancer Center at Johns...National Cancer Institute (NCI)TerminatedMetastatic Prostate Carcinoma | Prostate Adenocarcinoma | Stage IV Prostate Cancer | Hormone-Resistant Prostate CancerUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Millennium: The Takeda Oncology CompanyCompletedRecurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate CancerUnited States
-
Barbara Ann Karmanos Cancer InstituteCompletedRecurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate CancerUnited States
-
OHSU Knight Cancer InstituteNational Cancer Institute (NCI)TerminatedRecurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate CancerUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate CancerUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI); Millennium Pharmaceuticals, Inc.TerminatedRecurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate CancerUnited States
-
BayerCompletedBone Metastases | Hormone Refractory Prostate CancerItaly, Spain, Hong Kong, Canada, United Kingdom, France, Australia, United States, Germany, Brazil, Israel, Netherlands, Norway, Belgium, Sweden, Czech Republic, Poland, Singapore, Slovakia
-
Mayo ClinicCompletedProstate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate CancerUnited States
-
Barbara Ann Karmanos Cancer InstituteNational Cancer Institute (NCI)CompletedRecurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)WithdrawnRecurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Stage IV Prostate CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI); AEterna ZentarisCompletedRecurrent Prostate Cancer | Prostate Cancer | Hormone-resistant Prostate Cancer | Stage IV Prostate CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)UnknownRecurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Stage IV Prostate CancerUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedRecurrent Prostate Carcinoma | Stage I Prostate Cancer | Stage II Prostate Cancer | Hormone-Resistant Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Roswell Park Cancer InstituteMerck Sharp & Dohme LLCTerminatedRecurrent Prostate Cancer | Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate CancerUnited States